Please enter the email address you used to register, then we will send you a link to choose a new password
- Form 8-K
Cara Therapeutics plans to explore strategic alternatives. There are no meaningful development programs in the pipeline, analys...
Canaccord Genuity analyst Sumant Kulkarni downgrades Cara Therapeutics (NASDAQ:CARA) from Buy to Hold and lowers the price t...